Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 2/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
| ▸ | TSPO | P30536 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079819 | 0.82 | DHODH (0.36) | DHODHALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL6080476 | 0.80 | DHODH (0.34) | DHODHKDM4EMAPTRAB9ATDP1 | |
| SCHEMBL6080873 | 0.76 | ADORA2A (0.36) | CXCR2CXCR1PIN1KDM4E | |
| SCHEMBL6080453 | 0.75 | TSHR (0.40) | ALDH1A1KDM4EMAPTTDP1 | |
| SCHEMBL6080823 | 0.73 | NQO2 (0.40) | DHODHKDM4EMAPTRAB9ATDP1 | |
| SCHEMBL6080525 | 0.71 | PTGER1 (0.46) | MAPTTDP1 | |
| SCHEMBL6079712 | 0.71 | DHODH (0.47) | DHODHALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL6080122 | 0.68 | SLC22A12 (0.37) | CXCR2ALDH1A1PIN1KDM4EMAPT | |
| SCHEMBL26094546 | 0.66 | TSHR (0.40) | CXCR2CXCR1ALDH1A1 | |
| SCHEMBL6080139 | 0.66 | DHODH (0.36) | F11DHODHALDH1A1PIN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | F11 3054/4885DHODH 188/4885CXCR2 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.